APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Musculoskeletal Disorders

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for Musculoskeletal Disorders Industry Growth and Trends Forecast to 2032

22 December 202594 pages

Choose your research edition.

Industry ResearchDrugs for Musculoskeletal Disorders Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Musculoskeletal Disorders Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Drugs for Musculoskeletal Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Musculoskeletal Disorders Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Musculoskeletal Disorders Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Drugs for Musculoskeletal Disorders market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for Musculoskeletal Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for Musculoskeletal Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Musculoskeletal Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Musculoskeletal Disorders include Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer Inc, Amgen, AbbVie and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for Musculoskeletal Disorders market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for Musculoskeletal Disorders market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Musculoskeletal Disorders market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Musculoskeletal Disorders.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Drugs for Musculoskeletal Disorders market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for Musculoskeletal Disorders Market by Company

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer Inc

Amgen

AbbVie

UCB

Drugs for Musculoskeletal Disorders Segment by Type

OTC

Rx Drugs

Drugs for Musculoskeletal Disorders Segment by Application

Hospital

Retail Pharmacy

Drugs for Musculoskeletal Disorders Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Musculoskeletal Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Musculoskeletal Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Musculoskeletal Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Musculoskeletal Disorders manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Drugs for Musculoskeletal Disorders in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of OTC Table 2. Major Company of Rx Drugs Table 3. Global Drugs for Musculoskeletal Disorders Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (k units) Table 5. Global Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type (2021-2026) Table 6. Global Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (US$ Million) Table 7. Global Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type (2021-2026) Table 8. Global Drugs for Musculoskeletal Disorders Price by Type (2021-2026) & (US$/unit) Table 9. Global Drugs for Musculoskeletal Disorders Sales by Type (2027-2032) & (k units) Table 10. Global Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type (2027-2032) Table 11. Global Drugs for Musculoskeletal Disorders Sales by Type (2027-2032) & (US$ Million) Table 12. Global Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type (2027-2032) Table 13. Global Drugs for Musculoskeletal Disorders Price by Type (2027-2032) & (US$/unit) Table 14. North America Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (k units) Table 15. North America Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (k units) Table 17. Europe Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (k units) Table 21. Latin America Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Type (2021-2026) & (US$ Million) Table 24. Drugs for Musculoskeletal Disorders Industry Trends Table 25. Drugs for Musculoskeletal Disorders Industry Drivers Table 26. Drugs for Musculoskeletal Disorders Industry Opportunities and Challenges Table 27. Drugs for Musculoskeletal Disorders Industry Restraints Table 28. Global Drugs for Musculoskeletal Disorders Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Drugs for Musculoskeletal Disorders Revenue Market Share by Company (2021-2026) Table 30. Global Drugs for Musculoskeletal Disorders Sales by Company (2021-2026) & (k units) Table 31. Global Drugs for Musculoskeletal Disorders Sales Share by Company (2021-2026) Table 32. Global Drugs for Musculoskeletal Disorders Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Drugs for Musculoskeletal Disorders Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Drugs for Musculoskeletal Disorders Major Company Production Sites and Headquarters Table 35. Global Drugs for Musculoskeletal Disorders Company, Product Type & Application Table 36. Global Drugs for Musculoskeletal Disorders Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Drugs for Musculoskeletal Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Drugs for Musculoskeletal Disorders Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Drugs for Musculoskeletal Disorders Sales by Region (2021-2026) & (k units) Table 41. Global Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Region (2021-2026) Table 42. Global Drugs for Musculoskeletal Disorders Sales by Region (2021-2026) & (US$ Million) Table 43. Global Drugs for Musculoskeletal Disorders Sales Market Share in Value by Region (2021-2026) Table 44. Global Drugs for Musculoskeletal Disorders Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Drugs for Musculoskeletal Disorders Sales by Region (2027-2032) & (k units) Table 46. Global Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Region (2027-2032) Table 47. Global Drugs for Musculoskeletal Disorders Sales by Region (2027-2032) & (US$ Million) Table 48. Global Drugs for Musculoskeletal Disorders Sales Market Share in Value by Region (2027-2032) Table 49. Global Drugs for Musculoskeletal Disorders Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Drugs for Musculoskeletal Disorders Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (k units) Table 52. Global Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application (2021-2026) Table 53. Global Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (US$ Million) Table 54. Global Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application (2021-2026) Table 55. Global Drugs for Musculoskeletal Disorders Price by Application (2021-2026) & (US$/unit) Table 56. Global Drugs for Musculoskeletal Disorders Sales by Application (2027-2032) & (k units) Table 57. Global Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application (2027-2032) Table 58. Global Drugs for Musculoskeletal Disorders Sales by Application (2027-2032) & (US$ Million) Table 59. Global Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application (2027-2032) Table 60. Global Drugs for Musculoskeletal Disorders Price by Application (2027-2032) & (US$/unit) Table 61. North America Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (k units) Table 62. North America Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (k units) Table 64. Europe Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (k units) Table 68. Latin America Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Application (2021-2026) & (US$ Million) Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Drugs for Musculoskeletal Disorders Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Novartis Drugs for Musculoskeletal Disorders Product Portfolio Table 80. Novartis Recent Development Table 81. Merck Company Information Table 82. Merck Business Overview Table 83. Merck Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Merck Drugs for Musculoskeletal Disorders Product Portfolio Table 85. Merck Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Roche Drugs for Musculoskeletal Disorders Product Portfolio Table 90. Roche Recent Development Table 91. Eli Lilly Company Information Table 92. Eli Lilly Business Overview Table 93. Eli Lilly Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Eli Lilly Drugs for Musculoskeletal Disorders Product Portfolio Table 95. Eli Lilly Recent Development Table 96. Pfizer Inc Company Information Table 97. Pfizer Inc Business Overview Table 98. Pfizer Inc Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Pfizer Inc Drugs for Musculoskeletal Disorders Product Portfolio Table 100. Pfizer Inc Recent Development Table 101. Amgen Company Information Table 102. Amgen Business Overview Table 103. Amgen Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Amgen Drugs for Musculoskeletal Disorders Product Portfolio Table 105. Amgen Recent Development Table 106. AbbVie Company Information Table 107. AbbVie Business Overview Table 108. AbbVie Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. AbbVie Drugs for Musculoskeletal Disorders Product Portfolio Table 110. AbbVie Recent Development Table 111. UCB Company Information Table 112. UCB Business Overview Table 113. UCB Drugs for Musculoskeletal Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. UCB Drugs for Musculoskeletal Disorders Product Portfolio Table 115. UCB Recent Development Table 116. North America Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 117. North America Drugs for Musculoskeletal Disorders Sales by Country (2021-2026) & (k units) Table 118. North America Drugs for Musculoskeletal Disorders Sales Market Share by Country (2021-2026) Table 119. North America Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032) & (k units) Table 120. North America Drugs for Musculoskeletal Disorders Sales Market Share Forecast by Country (2027-2032) Table 121. North America Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026) & (US$ Million) Table 123. North America Drugs for Musculoskeletal Disorders Market Share by Country (2021-2026) Table 124. North America Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America Drugs for Musculoskeletal Disorders Market Share Forecast by Country (2027-2032) Table 126. Europe Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 127. Europe Drugs for Musculoskeletal Disorders Sales by Country (2021-2026) & (k units) Table 128. Europe Drugs for Musculoskeletal Disorders Sales Market Share by Country (2021-2026) Table 129. Europe Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032) & (k units) Table 130. Europe Drugs for Musculoskeletal Disorders Sales Market Share Forecast by Country (2027-2032) Table 131. Europe Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe Drugs for Musculoskeletal Disorders Market Share by Country (2021-2026) Table 134. Europe Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe Drugs for Musculoskeletal Disorders Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Country (2021-2026) & (k units) Table 138. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032) & (k units) Table 140. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific Drugs for Musculoskeletal Disorders Market Share by Country (2021-2026) Table 144. Asia-Pacific Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific Drugs for Musculoskeletal Disorders Market Share Forecast by Country (2027-2032) Table 146. Latin America Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 147. Latin America Drugs for Musculoskeletal Disorders Sales by Country (2021-2026) & (k units) Table 148. Latin America Drugs for Musculoskeletal Disorders Sales Market Share by Country (2021-2026) Table 149. Latin America Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032) & (k units) Table 150. Latin America Drugs for Musculoskeletal Disorders Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America Drugs for Musculoskeletal Disorders Market Share by Country (2021-2026) Table 154. Latin America Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America Drugs for Musculoskeletal Disorders Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Country (2021-2026) & (k units) Table 158. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032) & (k units) Table 160. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa Drugs for Musculoskeletal Disorders Market Share by Country (2021-2026) Table 164. Middle East and Africa Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa Drugs for Musculoskeletal Disorders Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Drugs for Musculoskeletal Disorders Distributors List Table 169. Drugs for Musculoskeletal Disorders Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Drugs for Musculoskeletal Disorders Image Figure 2. Global Drugs for Musculoskeletal Disorders Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Musculoskeletal Disorders Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Musculoskeletal Disorders Sales (2021-2032) & (k units) Figure 5. OTC Image Figure 6. Global OTC Sales YoY Growth (2021-2032) & (k units) Figure 7. Rx Drugs Image Figure 8. Global Rx Drugs Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Drugs for Musculoskeletal Disorders Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Drugs for Musculoskeletal Disorders Market Share by Type 2025 VS 2032 Figure 11. North America Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type in 2025 Figure 12. North America Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type in 2025 Figure 13. Europe Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type in 2025 Figure 14. Europe Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type in 2025 Figure 17. Latin America Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Drugs for Musculoskeletal Disorders Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 25. Retail Pharmacy Image Figure 26. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 27. Global Drugs for Musculoskeletal Disorders Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Drugs for Musculoskeletal Disorders Market Share by Application 2025 VS 2032 Figure 29. North America Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application in 2025 Figure 30. North America Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application in 2025 Figure 31. Europe Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application in 2025 Figure 32. Europe Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application in 2025 Figure 35. Latin America Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Market Share in Value by Application in 2025 Figure 39. North America Drugs for Musculoskeletal Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 40. North America Drugs for Musculoskeletal Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Drugs for Musculoskeletal Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Drugs for Musculoskeletal Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Drugs for Musculoskeletal Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. Europe Drugs for Musculoskeletal Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Drugs for Musculoskeletal Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Drugs for Musculoskeletal Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Asia-Pacific Drugs for Musculoskeletal Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Drugs for Musculoskeletal Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Drugs for Musculoskeletal Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Drugs for Musculoskeletal Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Latin America Drugs for Musculoskeletal Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Drugs for Musculoskeletal Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Drugs for Musculoskeletal Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Middle East and Africa Drugs for Musculoskeletal Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Drugs for Musculoskeletal Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Drugs for Musculoskeletal Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Drugs for Musculoskeletal Disorders Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Drugs for Musculoskeletal Disorders Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • OTC
  • Rx Drugs
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer Inc
  • Amgen
  • AbbVie
  • UCB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Musculoskeletal Disorders Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Drugs for Musculoskeletal Disorders Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Drugs for Musculoskeletal Disorders Market by Type
  6. 1.3.1 OTC
  7. 1.3.2 Rx Drugs
  8. 1.4 Global Drugs for Musculoskeletal Disorders Market Size by Type
  9. 1.4.1 Global Drugs for Musculoskeletal Disorders Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Drugs for Musculoskeletal Disorders Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Drugs for Musculoskeletal Disorders Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Drugs for Musculoskeletal Disorders Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Drugs for Musculoskeletal Disorders Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Drugs for Musculoskeletal Disorders Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Drugs for Musculoskeletal Disorders Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Drugs for Musculoskeletal Disorders Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Drugs for Musculoskeletal Disorders Industry Trends
  2. 2.2 Drugs for Musculoskeletal Disorders Industry Drivers
  3. 2.3 Drugs for Musculoskeletal Disorders Industry Opportunities and Challenges
  4. 2.4 Drugs for Musculoskeletal Disorders Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Drugs for Musculoskeletal Disorders Revenue (2021-2026)
  2. 3.2 Global Top Players by Drugs for Musculoskeletal Disorders Sales (2021-2026)
  3. 3.3 Global Top Players by Drugs for Musculoskeletal Disorders Price (2021-2026)
  4. 3.4 Global Drugs for Musculoskeletal Disorders Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Musculoskeletal Disorders Major Company Production Sites & Headquarters
  6. 3.6 Global Drugs for Musculoskeletal Disorders Company, Product Type & Application
  7. 3.7 Global Drugs for Musculoskeletal Disorders Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Musculoskeletal Disorders Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Musculoskeletal Disorders Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Musculoskeletal Disorders Tier 1, Tier 2, and Tier 3
4 Drugs for Musculoskeletal Disorders Regional Status and Outlook
  1. 4.1 Global Drugs for Musculoskeletal Disorders Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Drugs for Musculoskeletal Disorders Historic Market Size by Region
  3. 4.2.1 Global Drugs for Musculoskeletal Disorders Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Drugs for Musculoskeletal Disorders Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Drugs for Musculoskeletal Disorders Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Drugs for Musculoskeletal Disorders Forecasted Market Size by Region
  7. 4.3.1 Global Drugs for Musculoskeletal Disorders Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Drugs for Musculoskeletal Disorders Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Drugs for Musculoskeletal Disorders Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Drugs for Musculoskeletal Disorders by Application
  1. 5.1 Drugs for Musculoskeletal Disorders Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Drugs for Musculoskeletal Disorders Market Size by Application
  5. 5.2.1 Global Drugs for Musculoskeletal Disorders Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Drugs for Musculoskeletal Disorders Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Drugs for Musculoskeletal Disorders Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Drugs for Musculoskeletal Disorders Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Drugs for Musculoskeletal Disorders Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Drugs for Musculoskeletal Disorders Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Drugs for Musculoskeletal Disorders Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Drugs for Musculoskeletal Disorders Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Drugs for Musculoskeletal Disorders Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Drugs for Musculoskeletal Disorders Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Drugs for Musculoskeletal Disorders Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Roche
  20. 6.4.1 Roche Company Information
  21. 6.4.2 Roche Business Overview
  22. 6.4.3 Roche Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Roche Drugs for Musculoskeletal Disorders Product Portfolio
  24. 6.4.5 Roche Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly Drugs for Musculoskeletal Disorders Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
  31. 6.6 Pfizer Inc
  32. 6.6.1 Pfizer Inc Company Information
  33. 6.6.2 Pfizer Inc Business Overview
  34. 6.6.3 Pfizer Inc Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Inc Drugs for Musculoskeletal Disorders Product Portfolio
  36. 6.6.5 Pfizer Inc Recent Developments
  37. 6.7 Amgen
  38. 6.7.1 Amgen Company Information
  39. 6.7.2 Amgen Business Overview
  40. 6.7.3 Amgen Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Amgen Drugs for Musculoskeletal Disorders Product Portfolio
  42. 6.7.5 Amgen Recent Developments
  43. 6.8 AbbVie
  44. 6.8.1 AbbVie Company Information
  45. 6.8.2 AbbVie Business Overview
  46. 6.8.3 AbbVie Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 AbbVie Drugs for Musculoskeletal Disorders Product Portfolio
  48. 6.8.5 AbbVie Recent Developments
  49. 6.9 UCB
  50. 6.9.1 UCB Company Information
  51. 6.9.2 UCB Business Overview
  52. 6.9.3 UCB Drugs for Musculoskeletal Disorders Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 UCB Drugs for Musculoskeletal Disorders Product Portfolio
  54. 6.9.5 UCB Recent Developments
7 North America by Country
  1. 7.1 North America Drugs for Musculoskeletal Disorders Sales by Country
  2. 7.1.1 North America Drugs for Musculoskeletal Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Drugs for Musculoskeletal Disorders Sales by Country (2021-2026)
  4. 7.1.3 North America Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032)
  5. 7.2 North America Drugs for Musculoskeletal Disorders Market Size by Country
  6. 7.2.1 North America Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026)
  8. 7.2.3 North America Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Drugs for Musculoskeletal Disorders Sales by Country
  2. 8.1.1 Europe Drugs for Musculoskeletal Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Drugs for Musculoskeletal Disorders Sales by Country (2021-2026)
  4. 8.1.3 Europe Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Drugs for Musculoskeletal Disorders Market Size by Country
  6. 8.2.1 Europe Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026)
  8. 8.2.3 Europe Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Country
  2. 9.1.1 Asia-Pacific Drugs for Musculoskeletal Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Drugs for Musculoskeletal Disorders Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Drugs for Musculoskeletal Disorders Market Size by Country
  6. 9.2.1 Asia-Pacific Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Drugs for Musculoskeletal Disorders Sales by Country
  2. 10.1.1 South America Drugs for Musculoskeletal Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Drugs for Musculoskeletal Disorders Sales by Country (2021-2026)
  4. 10.1.3 South America Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032)
  5. 10.2 South America Drugs for Musculoskeletal Disorders Market Size by Country
  6. 10.2.1 South America Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026)
  8. 10.2.3 South America Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Country
  2. 11.1.1 Middle East and Africa Drugs for Musculoskeletal Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Drugs for Musculoskeletal Disorders Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Drugs for Musculoskeletal Disorders Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Drugs for Musculoskeletal Disorders Market Size by Country
  6. 11.2.1 Middle East and Africa Drugs for Musculoskeletal Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Drugs for Musculoskeletal Disorders Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Drugs for Musculoskeletal Disorders Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Drugs for Musculoskeletal Disorders Value Chain Analysis
  2. 12.1.1 Drugs for Musculoskeletal Disorders Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Drugs for Musculoskeletal Disorders Production Mode & Process
  7. 12.2 Drugs for Musculoskeletal Disorders Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Drugs for Musculoskeletal Disorders Distributors
  10. 12.2.3 Drugs for Musculoskeletal Disorders Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst